Advanced search
Publication Cover
Scandinavian Journal of Rheumatology Volume 49, 2020 - Issue 2
Submit an article Journal homepage
331
Views
6
CrossRef citations to date
0
Altmetric
Letters

Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report

M MoriyamaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, Shimane, JapanCorrespondence[email protected]
,
Y WadaInternal Medicine III, Shimane University Faculty of Medicine, Izumo, Shimane, Japan
,
T MinamotoDepartment of Obstetrics, Shimane University Faculty of Medicine, Izumo, Shimane, Japan
,
M KondoDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan
,
M HondaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan
&
Y MurakawaDepartment of Rheumatology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan;Internal Medicine III, Shimane University Faculty of Medicine, Izumo, Shimane, Japan
Pages 165-166 | Accepted 01 Jul 2019, Published online: 22 Aug 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
"Unexpectedly lower proportion of placental transferred tocilizumab relative to whole immunoglobulin G: a case report." Scandinavian Journal of Rheumatology, 49(2), pp. 165–166

Acknowledgement

This study was supported by research expenses provided by Shimane University.

Disclosure statement

MM has received speaking fees from Mitsubishi-Tanabe Pharmaceutical and Janssen Pharmaceutical and manuscript fees from Sanofi.  KM has received speaking fee from Eisai, Chugai Pharmaceutical, Mitsubishi-Tanabe Pharmaceutical, Bristol-Myers Squibb, Janssen Pharmaceutical, Astellas Pharmaceutical, Takeda Pharmaceutical, Nippon Kayaku, Daiichi-Sankyo, Asahi Kasei Pharmaceutical. and AbbVie Japan. HM received speaking fees from Asahi Kasei Pharmaceutical and Ono Pharmaceutical. MY received grants from Asahi Kasei Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Daiichi-Sankyo, Teijin Pharmaceutical, Eisai, Nippon Kayaku and Mitsubishi-Tanabe Pharmaceutical, instructor fees from Asahi Kasei Pharmaceutical, Kissei Pharmaceutical, Janssen Pharmaceutical, and speaking fees from Ono Pharmaceutical, Mitsubishi-Tanabe Pharmaceutical, Astellas Pharmaceutical, UCB Japan, Chugai Pharmaceutical, AbbVie Japan, Daiichi-Sankyo, Ayumi Pharmaceutical, Janssen Pharmaceutical, Takeda Pharmaceutical Sanofi, Teijin Pharma, Eli Lilly Japan and Eisai. WY and MT have no conflicts of interest to declare.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 171.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.